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Background: In the practical management of allergic rhinitis (AR), pharmacists are usually the first-line contact,
also because some medications are available as over the counter. Therefore, pharmacists may represent an
important resource, in mediating the interaction between patients and physicians. We evaluated the clinical/
demographic characteristics of patients with respiratory allergies who consulted their pharmacists as first-line
contact. A patient-oriented questionnaire was developed by a scientific committee including pharmacists, GPs,
allergists, pulmonologists and ENT specialists.
Methods: The questionnaire consisted of items covering the general aspects of AR. Allergic Rhinitis and its Impact
on Asthma guidelines were assumed as reference for diagnosis and therapy. The questionnaire was distributed to
pharmacies, and pharmacists were asked to deliver the questionnaire to all patients referring for nasal symptoms.
Results: 30 pharmacies were involved during the pollen season 2011, and 410 patients (55 % male) participated.
The most frequent complaints were 20 rhinitis (49 %) and conjunctivitis (29 %), followed by lower respiratory
symptoms (cough and/or dyspnea). Isolated conjunctival symptoms were present in only 22 % of patients. Among
patients with lower respiratory symptoms, cough was the most frequent, variously associated with upper respiratory
symptoms or overt dyspnea. Dyspnea alone was present in 16 % of patients. 39 % of patients had no physician-based
diagnosis. Oral antihistamines were the most used self-medication, followed by intranasal decongestants. 30 % of
respondents had used alternative medicines.
Conclusion: According to these data, AR is still considered a trivial disease, frequently self-managed, with over the
counter medications, not in line with guidelines. A physician-based diagnosis is present in about 60 % of patients.
Keywords: Respiratory allergy, Allergic rhinitis, Allergic asthma, PharmacistBackground
Respiratory allergic diseases (asthma/rhinitis) probably
represent in absolute the most frequent immune-
mediated disorders [1], and their prevalence is still
increasing worldwide, as recently underlined in the
GEIRD (Gene Environment Interactions in Respiratory
Diseases) epidemiological study [2]. The impact of
respiratory allergy is of particular relevance when
considering the costs, either direct (expenditure for
drugs, hospitalizations, access to medical care) or
indirect (absenteeism, presenteism, decreased school/* Correspondence: passalacqua@unige.it
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unless otherwise stated.work performance). Allergic Rhinitis (AR) is defined
as a symptomatic disorder of the nasal mucosa, due
to an IgE-mediated inflammation that follows the
contact with an offending allergen. Cardinal symp-
toms of AR are nasal itching, sneezing, rhinorrhea
and obstruction, and they are spontaneously reversible
or controlled by adequate treatment [3–5]. AR can be
frequently associated with other comorbidities, such
as rhinosinusitis which is present in about 20–30 %
patients [6], asthma (10–35 %) [7], and conjunctivitis.
Also polyposis and sleep disturbances [8,9], are not
rare, occurring in not less than 10 % of subjects. This
aspects make the diagnostic approach sometimes
particularly complex [10]. Nonetheless, AR is still
considered as a “trivial” disease, that can be easilyis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Template of the questionnaire used
QUESTION POSSIBLE ANSWERS
1 Gender • M
• F









4 Which symptom mainly
prompted you to go to
the pharmacy?
• Rhinitis (sneezing, runny






• Dyspnea (short breath)
5 How long before your
visit to the pharmacy did
the symptom appear?
• < 5 days
• 5-10 days
• 11-30 days
• > 30 days























• If you can not specify
the class, indicate
commercial names








Table 1 Template of the questionnaire used (Continued)







11 If for this problem you
usually care alone, why
do you?
• It is a trivial problem




• Just consult the
pharmacist
12 Do your symptoms affect
your everyday life?
• Not at all
• Moderately
• Heavily
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viders other than physicians. In this context, pharma-
cists are usually the first-line contact for AR patients
[3,11], also because, several medications (namely, oral/
local antihistamines and decongestants) are available as
“over the counter” [12]. Therefore, pharmacists with an
adequate preparation may represent an important
healthcare resource, in mediating the contact between
patients and physicians. This is especially true when a
more detailed diagnostic approach is needed. Based
on these considerations, we aimed at evaluating the
clinical/demographic characteristics of patients suf-
fering with respiratory allergies who consulted phar-
macists as first-line contact. This was done by a
questionnaire-based survey.
Methods
A patient-oriented questionnaire was developed by a
scientific committee in which convened pharmacists
(25 %), GPs (20 %), allergists (25 %), pulmunologists
(15 %) and ENT (15 %) specialists. The questionnaire
consisted of 12 items covering the main and general
aspects of AR, as shown in Table 1. The question-
naire was discussed and agreed by the Provincial
Board of Pharmacists of Brescia.
The Allergic Rhinitis and its Impact on Asthma
(ARIA) document was assumed as guideline for diag-
nostic and therapeutic approaches [3,10]. The question-
naire, as a paper sheet, was distributed to pharmacies
of the Brescia province and pharmacists were asked to
deliver the questionnaire to all patients referring for nasal
symptoms during the 2011 pollen season (February –
May). The participation into this survey was on a
voluntary basis and all the personal/demographic data
were kept strictly anonymous. The observational study
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Phisicians & Pharmacists Orders, according to the
Italian legislation.
Results
Thirty pharmacies, 54 % in the urban area of Brescia
and 46 % in the surroundings, participated in this
initiative. At the final collection, there were 410
respondent patients (55 % male, age range: 20–40
years), all referring to pharmacies during the spring
pollen season 2011 (February–May) for nasal/respira-
tory complaints (rhinitis, rhinosinusitis, asthma, con-
junctivitis). Of note, the majority of subjects belonged
to an age range characterized by active work/school/
sport activity. Out of the 410 patients, 19 % were
immigrants (4 % african, 3 % arab, 3 % asian, 2 %
latin american, 7 % eastern european). This is in line
to what previously observed in a cross-sectional study
performed in this geographical area [13]. According
to questionnaires, the most frequent complaints were
rhinitis (49 %) and conjunctivitis (29 %), followed by
lower respiratory symptoms (cough and/or dyspnea)
(Fig. 1). Rhinitis symptoms remained the main cause
of spontaneous access to the pharmacy (320 patients
out of 410 total, 76 % of patients with rhinitis),
responsible alone of 49 % of consultations, and as-
sociated with conjunctivitis in 27 % of the accesses
(Fig. 2a). Isolated conjunctival symptoms did not
appear as a relevant event, accounting for 29 % of
patients (Fig. 2b). Among patients with lower respi-
ratory symptoms, cough was the preeminent reason
for referral, and it was variously associated with upper
respiratory symptoms or overt dyspnea (Fig. 2c). On
the other hand, dyspnea alone was reported by 11 %
of patients (Fig. 2d) . There was a wide time spanFig. 1 Main Symptom reported by patients as reason for referral to pharmbetween the onset of symptoms and the seek for care
(Fig. 3), and in 39 % of patients no physician-based
diagnosis was declared, this underlining a high pro-
portion of self-diagnosis and self-management. Not-
ably, in 49 % of immigrants, the problem had been
not formally diagnosed, and 81 % were not treated by
a doctor. These patients were therefore underdiag-
nosed and undertreated. Even among immigrants,
rhinitis was the disease that led patients to the at-
tention of the pharmacist (Fig. 4). In general, Oral an-
tihistamines (over the counter in Italy) were the most
used self-medication drug, followed by intranasal de-
congestants (self medication in 22 % of patients)
(Fig. 5). Treatment options such as homeopathy or
alternative medicine had already been used or actually
used by 33 % of the respondents. Concerning
allergen-specific immunotherapy sublingual or sub-
cutaneous, only 12 % of the patients examined in our
study had used it. The pharmacist resulted to be the
first-line contact for 47 % of patients, whereas 42 %
of the respondents considered its problem as trivial,
and 11 % reported that GPs under evaluated nasal
symptoms. Finally, 28 % of the respondents con-
sidered AR as heavily impacting on the quality of life
and another 59 % judged the impact as moderate.
Discussion
AR is a common and frequent healthcare problem, af-
fecting almost 25 % of the general population [1,2].
The epidemiological impact lead to the search for a
better diagnostic definition and for an evidence-based
approach to its therapy, as done with the ARIA
guidelines [10], also considering that patients’ profile
is becoming more and more complex [14]. Nonethe-



































































Fig. 2 The main symptom that leaded patients to pharmacies is confirmed to be rhinitis (a). Conjunctivitis (b), cough (c), and dyspnea (d), often
associated with other allergic symptoms, in particular rhinitis
Fig. 3 Latency time between the onset of symptoms and the access to pharmacy. There is a wide distribution in the time period considered











Rhinitis Conjunctivitis Cough Shortness of breath  
Fig. 4 Even among immigrant patients rhinitis remains the predominant allergic disease leading patients to the attention of the pharmacist
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[15]. For those reasons AR is frequently self-managed
by patients, and the pharmacist, therefore, represent the
first-line contact. Guidelines dedicated to pharmacists
have been already published [4], but their real impact on
everydays’ practice have been not been specifically ad-
dressed so far. Thus, we attempted to evaluate the charac-
teristics, diagnosis, treatment profile and perception of AR
in a pharmacy setting. As expected, a vast majority of pa-
tients still retain the use of “over the counter” medicines
as the primary resource, being rhinitis a self-manageable
disease. Also, in line with the internationally increasing
use of Complementary-Alternative Medicines [16], ac-
cording to Italian data about one third of patients
approached these therapies for their diseases or symptoms
[17]. In general it is known that the reasons for the choice
of the use of complementary medicines are multiple,Fig. 5 Drug treatment mainly used/required by patients referred to the ph
decongestants (21 %) predominateamong which prevails the conviction of the lower level of
toxicity compared to conventional treatments [18].
Conclusion
According to our data, collected by pharmacists, a large
percentage of patients still consider AR as a trivial disease
[19], and recur to self-administered drugs (oral/nasal anti-
histamines and/or nasal vasoconstrictors), whereas an ap-
propriate diagnosis is made only in few cases. In particular,
the use of intranasal decongestants testifies for a non-
optimal management of AR, as well as the poor referral to
physicians. This is in line with elsewhere reported data
based on pharmacists’ experience [20–22]. Finally, the use
and knowledge of allergen-specific immunotherapy seems
to need improvement. Based on the present results, a more
strict and bi-directional collaboration between pharmacists
and physicians would be auspicable.armacy for respiratory allergies. Antihistamines (36 %) and topical nasal
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